Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the learndash domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/oquhzfvtvrzo/public_html/wp-includes/functions.php on line 6114

Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the login-customizer domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/oquhzfvtvrzo/public_html/wp-includes/functions.php on line 6114

Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the astra domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/oquhzfvtvrzo/public_html/wp-includes/functions.php on line 6114
Relapse – Leukaemia Care e-learning

Relapse

Relapse occurs when a patient initially responds to treatment, but after six months or more, the response stops.

Patients’ resistance or intolerance to their current TKI is normally due to their BCR-ABL1 mutation.

Patients usually respond well to being re-treated. Commonly following resistance to a TKI, haematologists will prescribe a different TKI.

NICE recommend nilotinib and bosutinib as treatment options for patients in any phase of their CML who have relapsed.